Breast cancer pathology patterns in Armenia.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12586-e12586
Author(s):  
Davit Zohrabyan ◽  
Samvel Bardakhchyan ◽  
Sergo Mkhitaryan ◽  
Liana Safaryan ◽  
Jemma Arakelyan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Medullary Carcinoma ◽  
Her2 Status ◽  
Leukocyte Infiltration ◽  
Luminal A ◽  
Luminal B ◽  
Epidemiological Characteristics ◽  
Armenian Women

e12586 Background: Breast cancer (BC) is the most common malignancy among the women in Armenia (AM). Currently there is a knowledge gap regarding the morphology distribution of the BC in AM. Methods: The data on patients with BC diagnosed in 2015-2016 in the pathology lab “Davidyants Labs” in AM were retrospectively reviewed. Pts with Her2+ results by IHC were excluded from the study, due to unavailability to perform FISH or CISH analyses. Overall 361 pathology reports were evaluated. Results: The median age was 54 years; range [19-82]. Histopathological subtypes were defined for 305 pts, from which lobular carcinoma 57.4% of cases (175/305), ductal carcinoma 26.9% (82/305), mucinous carcinoma 2.6% (8/305), mixed type carcinoma (lobular and ductal) 2.6% (8/305), DCIS 2% (n = 6/305), non specified carcinoma 2% (6/305), medullary carcinoma 1% (n = 3/305) and others 5.6% (17/305). Within the cohort 8.5% (23/270) were grade 1, 65.9% grade 2 (178/270); 25.6% grade 3 (n = 69/270). Vascular or lymphatic invasion was present in 59.5% (50/84) and 64.7% (55/85), respectively. Staging distribution, based on pT pN data for 92 pts who went to primary surgery, was: 0 stage 7.6% (7/92), I stage 22.8% (21/92), II stage 41.3% (38/92), III stage 28.3% (26/92). Staging distribution based on ypT ypN data for 27 pts who went to surgery after neoadjuvant chemo was 0 stage 25.9% (7/27), I stage 18.5% (5/27), II stage 29.6% (8/27), III stage 25.9% (7/27). ER and PR were defined for 244 patients. ER positive 89.8% (219/244) of cases, PR pos. 73% (178/244), ER/PR pos. 72.5% (177/244) cases. Her receptor was defined for 237 patients. Her3+ 16.9% (40/237); Her2+ 12.7% (30/237); Her1+ 38% (90/237); Her0 32.5% (n = 77/237). We could not evaluate Her2+ status by FISH or CISH, so these results were excluded from the analysis. Ki67 was low (≤20) in 42.1% (101/240) of cases and high ( > 20) in 57.9% (139/240). Within the group Luminal A type was 41.4% (84/203); Luminal B 32.5% (66/203); Her positive 19.7% (40/203) and triple negative 6.4% (13/203). p53 and perineural invasion (Pn) was present in 32% (16/50) and 52% (26/50), respectively. Tumor leukocyte infiltration was determined for 16 patients. Leukocyte infiltration was positive in 43.7% (7/16) cases, negative in 25% (4/16) cases, minimal in 31.3% cases (5/16). Conclusions: BC in Armenian women presents with different epidemiological characteristics in comparison with other ethnicities. Lobular type BC is the most frequent type among Armenian women, however, differential diagnosis between lobular/ductal carcinomas was done without IHC (E-Cadherin), which rises the need for further studies on that regard.

scholarly journals LACTOFERRIN EXPRESSION IN BREAST CANCER IN RELATION TO BIOLOGIC PROPERTIES OF TUMORS AND CLINICAL FEATURES OF DISEASE

2016 ◽  
Vol 38 (3) ◽  
pp. 181-186 ◽  
Author(s):  
L A Naleskina ◽  
N Yu Lukianova ◽  
S O Sobchenko ◽  
D M Storchai ◽  
V F Chekhun
Keyword(s):  
Breast Cancer ◽  
Clinical Features ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Strongly Correlated ◽  
Luminal A ◽  
Clinical Criteria ◽  
Luminal B ◽  
Course Materials ◽  
Er Positive

Aim: To determine the patterns of lactoferrin (LF) expression in breast cancer (BC) in relation to biologic properties of the neoplasms and clinical features of the disease course. Materials and Methods: Clinical specimens of 266 BC patients (115 patients with BC of stages I–II — retrospective study, and 151 BC patients — prospective study) were analyzed. Morphological, immunohistochemical and statistical methods were used. Results: The number of LF-positive tumors in retrospective and prospective groups was similar (52.1 and 52.8%, respectively). Among common clinical criteria for prognosis of the disease outcome in BC patients (patient’s age; stage of the disease; histological type, differentiation grade, receptor status; presence of metastases), a strong correlation was found only between expression indexes of LF and estrogen receptors (ER). In ER-positive tumors expression of LF was significantly higher than in ER-negative tumors (35 vs 18%). 5-Year survival rate of BC patients was higher in LF-positive group (70 vs 52% in LF-negative group). The presence of regional metastasis tended to correlate with an increased number of LF-positive tumors. In the patients with invasive ductal carcinoma, expression level of LF moderately correlated with occurrence of luminal A subtype (r = 0.43), while in the patients with invasive lobular carcinoma this index strongly correlated with occurrence of luminal B subtype (r = 0.71). LF expression correlated positively with low and moderate differentiation grade of luminal B or basal tumors, and negatively with luminal B or basal tumors of high differentiation grade (r = −0.57 and −0.63, respectively). Conclusion: It has been shown that LF expression in breast tumors correlated with life expectancy of BC patients and important physiologic and clinical features of the disease, while the character of such relation strongly depended on molecular phenotype of tumor, i.e. luminal A, luminal B or basal.

Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2- primary breast cancer.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 141-141
Author(s):  
Katsuhiko Nakatsukasa ◽  
Tetsuya Taguchi ◽  
Hiroshi Koyama ◽  
Seiichi Imanishi ◽  
Kouichi Sakaguchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Primary Breast Cancer ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Dose Intensity ◽  
Completion Rate ◽  
Luminal A ◽  
Luminal B ◽  
Triple Negative Subtype

141 Background: Recently, docetaxel plus cyclophosphamide (TC) has been established as a standard regimen for adjuvant chemotherapy in HER2- operable breast cancer. However, the efficacy and tolerability of TC as neoadjuvant chemotherapy (NAC) remains unclear. We performed a prospective study of TC NAC in HER2- primary breast cancer. Methods: Eligible patients had HER2- invasive breast cancer that measured more than 1cm, less than 7cm and N0~N1 clinically between July, 2011 and February, 2014. Four cycles of TC(75 and 600 mg/m2) were administered intravenously every 3 weeks as NAC. We investigated the pathological complete response(pCR) of primary breast tumors. pCR was defined as no histological evidence of invasive carcinoma, or the appearance of only ductal carcinoma in situ. The cut-off value of Ki67 index between luminal A and luminal B was defined 20%. Results: We enrolled 52 patients. The completion rate for 4 cycles of TC was 94.2% ( 49 of 52). Relative dose intensity was 99.1% for TC therapy. Forty nine patients were classified according to breast cancer subtype before the estimation. Overall pCR rate was 16.3 %( 8 of 49 ) . pCR rate for patients with luminal A ( ER+, Ki67 low and HER2- ), luminal B ( ER+, Ki67 high and HER2- ) and triple negative ( ER- and HER2- ) were 0%( 0 of 12 ), 4.3 %( 1 of 23 ) and 50.0 %( 7 of 14 ), respectively pCR was achieved in almost triple negative patients. Conclusions: The pCR rate of TC was not so high, regardless of the high completion rate. In this study, TC was effective against triple negative subtype, showing a high pCR rates, compared with luminal subtype. In conclusion, the efficacy of TC NAC in HER2- primary breast cancer is limited, and triple negative subtype might be the good target. Clinical trial information: UMIN000013261.

scholarly journals Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists

2020 ◽  
Author(s):  
Karen S Johnson ◽  
Emily F Conant ◽  
Mary Scott Soo
Keyword(s):  
Breast Cancer ◽  
Molecular Subtypes ◽  
Disease Free Survival ◽  
Response To Treatment ◽  
Her2 Status ◽  
Imaging Features ◽  
Luminal A ◽  
Luminal B ◽  
Her2 Breast Cancer ◽  
Er Expression

Abstract Gene expression profiling has reshaped our understanding of breast cancer by identifying four molecular subtypes: (1) luminal A, (2) luminal B, (3) human epidermal growth factor receptor 2 (HER2)-enriched, and (4) basal-like, which have critical differences in incidence, response to treatment, disease progression, survival, and imaging features. Luminal tumors are most common (60%–70%), characterized by estrogen receptor (ER) expression. Luminal A tumors have the best prognosis of all subtypes, whereas patients with luminal B tumors have significantly shorter overall and disease-free survival. Distinguishing between these tumors is important because luminal B tumors require more aggressive treatment. Both commonly present as irregular masses without associated calcifications at mammography; however, luminal B tumors more commonly demonstrate axillary involvement at diagnosis. HER2-enriched tumors are characterized by overexpression of the HER2 oncogene and low-to-absent ER expression. HER2+ disease carries a poor prognosis, but the development of anti-HER2 therapies has greatly improved outcomes for women with HER2+ breast cancer. HER2+ tumors most commonly present as spiculated masses with pleomorphic calcifications or as calcifications alone. Basal-like cancers (15% of all invasive breast cancers) predominate among “triple negative” cancers, which lack ER, progesterone receptor (PR), and HER2 expression. Basal-like cancers are frequently high-grade, large at diagnosis, with high rates of recurrence. Although imaging commonly reveals irregular masses with ill-defined or spiculated margins, some circumscribed basal-like tumors can be mistaken for benign lesions. Incorporating biomarker data (histologic grade, ER/PR/HER2 status, and multigene assays) into classic anatomic TNM staging can better inform clinical management of this heterogeneous disease.

scholarly journals Epidemiological profile of aged women with breast cancer in a private clinic in Criciúma/sc

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Maristela Harder Peters ◽  
Giorgia Emilia Klering ◽  
Thamyra Manenti Bonfante
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Elderly Women ◽  
Ductal Carcinoma ◽  
Private Clinic ◽  
The Body ◽  
Luminal A ◽  
Aged Patients ◽  
The Mean ◽  
Epidemiological Characteristics

Objectives: Breast cancer is the most common cancer among women, gradually increasing its incidence in the aged population. This study aims to analyze the epidemiological characteristics of patients over 60 years of age with breast cancer in a private clinic in the city of Criciúma, Santa Catarina. Methods: This is a retrospective observational study, with collection of primary and secondary data and a quantitative approach. The sample was obtained through the analysis of 76 medical records and questionnaires, between 2014 and 2018. Results: The mean age of the patients was 70.39 years. The mean age of menarche and menopause was 13.23 and 49.48 years, respectively. Regarding the body mass index, 38.4% had some degree of obesity. Most elderly women (81.8%) were non-smokers. Evenly, 92.3% were non-alcoholics. Most cancers were detected by mammography (39.3%). Conservative surgery was predominant (74.2%). The association between radiotherapy and hormone therapy was the predominant adjuvant therapy (48.7%). Neoadjuvance was performed in 15 patients, 9 of whom underwent neoadjuvant chemotherapy (60.0%). The most used hormone therapy was anastrozole (88.9%). The most common side effects related to hormone therapy were isolated muscle pain (35.7%) and associated hot flushes (21.4%). There was a predominance of invasive ductal carcinoma (59.2%) and Luminal A subtype (43.6%). Conclusion: Aged patients usually present with smaller and less aggressive tumors, mostly submitted to less aggressive treatments.

scholarly journals Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma

2018 ◽  
Author(s):  
Iris Rabinovich ◽  
Ana Paula Martins Sebastião ◽  
Rubens Silveira Lima ◽  
Cícero de Andrade Urban ◽  
Eduardo Schunemann Junior ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Ductal Carcinoma ◽  
Molecular Subtypes ◽  
Histological Grade ◽  
Clinical Aspects ◽  
Stem Cell Markers ◽  
Luminal A ◽  
Luminal B

Breast cancer is a very heterogeneous disease. The intrinsic molecular subtypes can explain the intertumoral heterogeneity and the cancer stem cell (CSC) hypothesis can explain the intratumoral heterogeneity of this kind of tumor. CD44+/CD24- phenotype and ALDH1 expression are the major CSC markers described in invasive breast cancer. In the present study, 144 samples of invasive breast carcinoma, no special type were distributed in 15 tissue microarrays (TMA) and then evaluated for expression of the CD44+/CD24- phenotype and ALDH1 to understand the importance of these CSC markers and the clinical aspects of breast cancer. The samples were classified into four molecular subtypes according to clinicopathological criteria: Luminal A, Luminal B, HER2, and Basal-like. A statistical association was found between the molecular subtypes and the CSC markers, with HER2 the most frequent subtype for both markers. ALDH1 was also associated with other poor prognostic variables, such as a high histological grade and larger tumors, but it was not associated with the patients’ prognosis in this sample and nor was the CD44+/CD24- phenotype in a multivariate analysis. There are still many controversies about the role of these markers in breast cancer molecular subtypes. The identification of these populations of cells, through immunohistochemical markers, can help to better understand the CSC theory in clinical practice and, in the near future, contribute to developing new target therapies.    

Application of Ultrasonography in the Pathological Study of Breast Cancer in Female Patients with Breast Lesions

2020 ◽  
Vol 10 (4) ◽  
pp. 947-953
Author(s):  
Yajuan Wang ◽  
Yuan Fu ◽  
Guangsen Li ◽  
Tianlang Jin
Keyword(s):  
Breast Cancer ◽  
Blood Flow ◽  
Invasive Ductal Carcinoma ◽  
Invasive Lobular Carcinoma ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Medullary Carcinoma ◽  
Pathological Classification ◽  
Significant Difference ◽  
The Relationship

The retrospective analysis of the ultrasonographic features of 108 cases of breast cancer confirmed by surgery and pathology, namely the relationship between mass boundary, posterior echo, calcification and blood flow signal and pathological type, was to explore the features of ultrasound sonography of breast cancer. The link between pathological typing. The results of the study showed that the ultrasound showed that the border of the nvasive ductal carcinoma was mostly burr-like. The ultrasound showed that the border of the invasive lobular carcinoma was mostly strong echo halo. The medullary carcinoma had a clear boundary, while the intraductal carcinoma showed more unclear borders. There was no significant difference in the relationship between the boundary of the mass and the pathological types. Ultrasound of invasive ductal carcinoma and invasive lobular carcinoma showed a posterior echo attenuation, and medullary carcinoma showed more posterior echo enhancement. The relationship between the echo of the posterior mass of the tumor and the pathological types was statistically different. The detection rate of ultrasound calcification in invasive ductal carcinoma and invasive lobular carcinoma was higher. The calcification in medullary carcinoma was less common. The calcification in the pathology of intraductal carcinoma was better. High, but ultrasound can only detect half of it. There was no significant difference in the relationship between calcification and pathological types in the tumor; ultrasound showed that most of the blood flow signals were abundant, suggesting that there was no statistical difference between the blood flow classification and the pathological classification of the tumor. The results of the thesis indicate that the ultrasound characteristics of breast cancer have a high diagnostic value for its pathological classification.

scholarly journals Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

2015 ◽  
Vol 33 (25) ◽  
pp. 2772-2779 ◽  
Author(s):  
Otto Metzger Filho ◽  
Anita Giobbie-Hurder ◽  
Elizabeth Mallon ◽  
Barry Gusterson ◽  
Giuseppe Viale ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Early Stage ◽  
Lobular Carcinoma ◽  
Relative Effectiveness ◽  
Disease Free Survival ◽  
Luminal A ◽  
Ki 67 ◽  
Cox Models ◽  
Luminal B ◽  
Breast International Group

Purpose To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients with invasive ductal or lobular carcinoma. Patients and Methods Patients diagnosed with early-stage invasive ductal carcinoma (IDC) or classic invasive lobular carcinoma (ILC) who were randomly assigned onto the Breast International Group (BIG) 1-98 trial and who had centrally reviewed pathology data were included (N = 2,923). HER2-negative IDC and ILC were additionally classified as hormone receptor–positive with high (luminal B [LB] –like) or low (luminal A [LA] –like) proliferative activity by Ki-67 labeling index. Survival analyses were performed with weighted Cox models that used inverse probability of censoring weighted modeling. Results The median follow-up time was 8.1 years. In multivariable models for disease-free survival (DFS), significant interactions between treatment and histology (ILC or IDC; P = .006) and treatment and subgroup (LB like or LA like; P = .01) were observed. In the ILC subset, there was a 66% reduction in the hazard of a DFS event with letrozole for LB (hazard ratio [HR], 0.34; 95% CI, 0.21 to 0.55) and a 50% reduction for LA subtypes (HR, 0.50; 95% CI, 0.32 to 0.78). In the IDC subset, there was a significant 35% reduction in the hazard of a DFS event with letrozole for the LB subtype (HR, 0.65; 95% CI, 0.53 to 0.79), but no difference between treatments was noted for IDC and the LA subtype (HR, 0.95; 95% CI, 0.76 to 1.20). Conclusion The magnitude of benefit of adjuvant letrozole is greater for patients diagnosed with lobular carcinoma versus ductal carcinoma.

scholarly journals Comparative analysis of the receptor status of the primary focus and synchronous axillary metastases in breast cancer patients

2020 ◽  
Vol 24 (3-6) ◽  
pp. 74-78
Author(s):  
Yu. S. Krumin’ ◽  
V. A. Khailenko ◽  
N. A. Kozlov ◽  
G. Yu. Cheremis ◽  
D. V. Khailenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Proliferative Activity ◽  
Molecular Subtype ◽  
Her2 Status ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Her2 Positive ◽  
Axillary Metastases ◽  
Receptor Status ◽  
Luminal B

The aim of the investigation. To study concordance of surrogate molecular subtype in the pairs of primary and synchronous axillary metastases in patients with invasive breast cancer (IBC). Materials and methods. Retrospective analysis included 80 patients aged 28 to 90 years (average age 40.35.3 years) with a first-time diagnosed IBC who underwent surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology during 20162018 years. None of the patients received any neoadjuvant drug therapy. The pathological evaluation of the estrogen receptors (ER), progesterone receptor (PR), HER2 expression and estimation of proliferative activity (Ki-67 index) with subsequent assignment to surrogate subtypes were performed according to ASCO/CAP protocols and the recommendations of the 20132019 San-Gallen Conference on treatment of Early Breast Cancer. Results. Preliminary results of our study revealed therapeutically significant changes in hormone receptor status, HER2-status and proliferative activity in 12.5% of cases of Luminal A type IBC, 20% of Luminal B/HER2-positive and 4% of Luminal B/Her2-negative subtypes of IBC.

Methylation RE in serum of patients with breast cancer and relation with molecular phenotype and worse prognostic factors.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 224-224
Author(s):  
J. Martínez-Galan ◽  
B. Torres-Torres ◽  
R. Del Moral ◽  
M. I. Núñez ◽  
S. Ríos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Gene Promoter ◽  
Therapy Resistance ◽  
Her2 Status ◽  
Molecular Phenotype ◽  
Luminal A ◽  
Cancer Subtypes ◽  
Luminal B

224 Background: To determine whether Estrogen Receptor (ESR1) (+) and ESR1(-) status relates to epigenetic changes in breast cancer-related genes and to correlate with molecular breast cancer subtypes. Methods: Since January/02 to June/05, we quantified methylation levels ERS1 gene in serum of 92 pts breast cancer. A PCR quantitative technique was used to analyze levels of methylation gene. We also examined and correlationed the expression of ESR1 in tumors by immunohistochemistry with molecular phenotype. Results: Median age was 58 years (32-88); 69% were postmenopausal women. Nodal involvement (N0; 63%, N1; 30%, N2; 7%), tumor size (T1; 58%, T2; 35%, T3; 4%, T4; 4%) and grade (G1; 20%, G2; 37%, G3; 30%). Of the cases, 37 pts (40%) were Luminal A (LA), 32 pts (33%) Luminal B (LB), 14 pts (15%) Triple-negative (TN) and 9pts (10%) HER2+. The methylated ESR1 in serum was significantly associated with ESR1(-) in breast tumors >80% (p=0.0179). Methylation ESR1 was preferably associated with TN (80%) and HER2+ (60%) subtype. Nevertheless unmethylation ESR1 was found more frequently in LA (71%) and LB (59%) phenotype. With a median follow up of 5 years, we found worse overall survival (OS) with more frequent ESR1 methylation gene (p>0.05), Luminal A; ESR1 Methylation OS at 5 years 81% vs 93% when was ESR1 Unmethylation. Luminal B; ESR1 Methylation 86% SG at 5 years vs 92% in Unmethylation ESR1. Triple negative; ESR1 Methylation SG at 5 years 75% vs 80% in unmethylation ESR1. HER2; ESR1 Methylation SG at 5 years was 66.7% vs 75% unmethylation ESR1. Conclusions: Gene promoter region hypermethylation is a significant event in primary breast cancer. However, its impact on tumor progression and potential predictive implications remain relatively unknown. Our study identifies the presence of variations in global levels of methylation promoters ESR1 genes in breast cancer with different phenotype classes and shows that these differences have clinical significance. Although numerous issues remain to be resolved, quantitative measurement of circulating methylated DNA may be of significance in the assessment and search of targeted therapy resistance related to ESR1 and HER2 status by epigenetic or transcriptional cancer therapy.

Evaluation of prognostic significance of microRNA in tumors of luminal, primary operable breast cancer without Her2 neu overexpression in postmenopausal women.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12558-e12558
Author(s):  
Elena P. Ulianova ◽  
Vasilij V. Tokmakov ◽  
Iuliana S. Shatova ◽  
Aleksandr B. Sagakyants ◽  
Anna S. Goncharova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Molecular Subtypes ◽  
Prognostic Significance ◽  
Luminal A ◽  
Relative Expression ◽  
Luminal B ◽  
Diagnostic Panel ◽  
Group 2 ◽  
Group 1

e12558 Background: Breast cancer (BC) is associated with miRNAs, the qualitative and quantitative analysis of which shows significant differences between molecular subtypes, as well as between miRNAs circulating in the bloodstream and detected in tumor tissue. Since there is no clear characteristics for markers of luminal B primary operable BC without Her 2 neu overexpression, our purpose was an evaluation of prognostic significance of miRNA-21, 221, 20a, 200a, 196a in such postmenopausal patients in order to create a diagnostic panel. Methods: The study included 120 samples of healthy tissues of patients with luminal A BC (group 1, mean age 76.16±3.14 years) and tumor tissues of patients with luminal B BC (group 2, mean age 69.5±3.2 years); invasive ductal carcinoma in all patients. The expression status was analyzed using 5 mioRNA markers associated, according to the literature, with various molecular subtypes of BC (miRNA-21, 221, 20a, 200a, 196a). The Thermo Scientific PureLink RNA Mini Kit was used for the total RNA isolation. The reverse transcription reaction was performed using the ImProm-II Reverse Transcriptase kit (Promega). The Livak/2 method was used to assess the relative expression of miRNAs. Results: The average relative expression was: miRNA-21 in group 1 – 0.2±0.01, group 2 – 1.5±0.05; miRNA- 221 in group 1 – 0.19±0.02, group 2 – 0.43±0.04; miRNA -20a in group 1 – 0.12±0.01, group 2 – 0.13±0.01, miRNA -200a in group 1 – 0.22±0.02, group 2 – 0.96±0.06; miRNA- 196a in group 1 – 1.06±0.02, group 2 – 1.56±0.04. The differences between the groups were statistically significant (p = 0.0001); the difference was statistically insignificant only for miRNA -20a (p = 0.159955). Conclusions: Results of the study allow considering the overexpression of miR-21, 221, 200a and 196a and the relatively low expression of miR-20a as diagnostic markers for a diagnostic panel for luminal B BC without overexpression of HER2/neu.

Sign in / Sign up

Export Citation Format

Share Document